Navigation Links
Imagenetix, Inc. Appoints Bill Toomey to Its Board of Directors
Date:6/30/2011

SAN DIEGO, June 30, 2011 /PRNewswire/ -- Imagenetix, Inc. (OTCBB:IAGX) announced today it has appointed Bill Toomey to its board of directors.

Commenting on the appointment, Mr. William Spencer, Imagenetix Chief Executive Officer said, "We are pleased that Bill has agreed to join our board and bring to us his extensive experience with Fortune 500 health related companies.  We will benefit greatly from his past experiences and high level business contacts to help position our proprietary health technologies."  

Mr. Toomey stated, "I certainly look forward to having a role on the Imagenetix board as I consider it to be advancing the cause of fitness products and other research oriented formulas that are an important part of the growing use of natural products to affect better health."

About Bill Toomey

Bill has used global influence as a world class athlete and leader of the International Olympic movement to benefit many.  He was the 1968 Olympic gold medalist in the decathlon, a past Sullivan Award winner (top USA athlete), ABC Athlete of the Year, and the Associated Press Amateur and Professional Athlete of the Year.  He is a past president of the International Olympic Committee's Alumni Association; was a Presidential advisor to the Peace Corps and a member of Gerald Ford's Presidential Commission on Olympic Sport. Bill received a Master's Degree from Stanford University and currently lectures at the University of California Davis.

About Imagenetix

Imagenetix, based in San Diego, California, is an innovator of scientifically tested, natural-based, proprietary, bioceutical products developed to enhance human health on a global basis.  Imagenetix develops and formulates propriety over-the-counter topical creams, skincare products and nutritional supplements to be marketed globally through multiple channels of distribution.  In addition, the company develops patentable compounds for entering into licensing agreements with Fortune 500 companies.

Certain matters in this news release are forward-looking statements which are subject to risks and uncertainties that could cause actual results to vary materially from those projected.  Such risks and uncertainties include, but are not limited to, adverse fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, the size and timing of customer contracts, new or increased competition, changes in market demand, and seasonality of purchases of the company's products and services.  Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in the company's SEC filings, including its Form 10-K for the year ended March 31, 2011.ContactImagenetix Investor Relations

William P. Spencer(858) 385-2797

Chief Executive OfficerImagenetix, Inc.Tel: (858) 674-8455
'/>"/>

SOURCE Imagenetix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Imagenetix, Inc. Reports Second Quarter 2011 Results
2. Imagenetix, Inc. Reports First Quarter 2011 Results
3. Imagenetix, Inc. to Present at the 2009 RedChip New York Equities Conference
4. Imagenetix, Inc. Announces Interview With Bloomberg Radio
5. Imagenetix, Inc. Reports First Quarter 2010 Results
6. Imagenetix, Inc. Reports Second Quarter and Six Month Results
7. Oramed Pharmaceuticals Appoints Dr. Michael Berelowitz as Chairman of Scientific Advisory Board
8. Crescendo Biologics Appoints Matthew Roe as Chief Business Officer
9. Synthetic Genomics Inc. Appoints Joseph Mahler as Chief Financial Officer
10. Asmacure Ltee Appoints Pharmaceutical and Biotechnology Industry Veteran Martin Driscoll as CEO
11. AquaStar Holdings, Inc. Subsidiary Appoints Former Beckman Coulter Executive as Vice President of Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the ... at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application ... team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... 2016 Andrew D ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free validated ... will showcase its product’s latest features from June 26 to June 30, 2016 ... on Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug ...
Breaking Biology Technology:
(Date:6/22/2016)... ANGELES , June 22, 2016 /PRNewswire/ ... identity management and verification solutions, has partnered ... edge software solutions for Visitor Management, Self-Service ... provides products that add functional enhancements ... partnership provides corporations and venues with an ...
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
(Date:6/2/2016)... LONDON , June 2, 2016 ... has awarded the 44 million US Dollar project, ... Security Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... world leader in the production and implementation of Identity Management ... in January, however Decatur was selected ...
Breaking Biology News(10 mins):